{"id":"sct400-plus-chop","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Neutropenia"},{"rate":"20-40%","effect":"Thrombocytopenia"},{"rate":"20-40%","effect":"Anemia"},{"rate":"10-30%","effect":"Fatigue"},{"rate":"10-30%","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL4594604","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"SCT400 works by inhibiting the anti-apoptotic function of BCL-2, allowing for programmed cell death in cancer cells. CHOP is a traditional chemotherapy regimen that targets rapidly dividing cancer cells.","oneSentence":"SCT400 is a small molecule inhibitor of the BCL-2 family, while CHOP is a combination chemotherapy regimen consisting of cyclophosphamide, doxorubicin, vincristine, and prednisone.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:52:48.973Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory diffuse large B-cell lymphoma"},{"name":"Relapsed or refractory follicular lymphoma"}]},"trialDetails":[{"nctId":"NCT02772822","phase":"PHASE3","title":"A Study Comparing the Efficiency and Safety of S-CHOP(Cyclophosphamide, Hydroxydaunomycin, Oncovin, and Prednisone) Versus R-CHOP in Untreated CD20(Cluster of Differentiation Antigen 20)-Positive DLBCL Patients","status":"UNKNOWN","sponsor":"Sinocelltech Ltd.","startDate":"2016-06","conditions":"Diffuse Large B Cell Lymphoma","enrollment":330}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SCT400 plus CHOP","genericName":"SCT400 plus CHOP","companyName":"Sinocelltech Ltd.","companyId":"sinocelltech-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SCT400 is a small molecule inhibitor of the BCL-2 family, while CHOP is a combination chemotherapy regimen consisting of cyclophosphamide, doxorubicin, vincristine, and prednisone. Used for Relapsed or refractory diffuse large B-cell lymphoma, Relapsed or refractory follicular lymphoma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}